文献速递肝病

泛PPAR激动剂lanifibranor改善实验性晚期慢性肝病的门脉高压与肝纤维化

Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.
PubMed 文献 · J Hepatol · 2020-12-02

在TAA和cBDL两种肝硬化大鼠模型及人肝硬化肝细胞中,泛PPAR激动剂lanifibranor(100 mg/kg/天,口服14天)显著降低门静脉压力(-15%,p=0.003)且不减少门脉血流,减少腹水、改善肝窦内皮细胞和肝星状细胞表型、减轻肝脏炎症,并促进纤维化消退(-32%,p=0.020);人肝硬化肝细胞经lanifibranor处理后表型亦改善。

要点

  • lanifibranor降低肝硬化大鼠门静脉压力15%而不减少门脉血流,提示肝血管阻力改善。
  • lanifibranor促进纤维化消退32%,并减少腹水、改善LSEC和HSC表型及肝脏炎症。
  • 人肝硬化肝细胞经lanifibranor处理后表型改善,支持其临床评估。

核心结论

  • lanifibranor在失代偿期肝硬化临床前模型中改善纤维化和门脉高压,人肝细胞结果支持其用于ACLD治疗的临床评估。

研究设计与样本

  • 研究使用TAA或cBDL诱导的肝硬化大鼠,随机接受lanifibranor(100 mg/kg/天,口服)或溶媒14天,每组n=12。
  • 同时评估人肝硬化患者分离的肝细胞经lanifibranor或溶媒处理后的表型。

主要发现

  • TAA肝硬化大鼠接受lanifibranor后门静脉压力较溶媒组显著降低15%(p=0.003),门脉血流未减少。
  • lanifibranor治疗TAA大鼠腹水减少,LSEC和HSC表型改善,肝微血管功能改善,肝脏炎症减轻。
  • lanifibranor治疗TAA大鼠肝纤维化显著消退32%(p=0.020)。
  • 上述发现在cBDL大鼠模型及人肝硬化肝细胞中得到验证,人肝细胞经lanifibranor处理后表型改善。

临床怎么用

  • lanifibranor有望成为改善ACLD门脉高压和肝纤维化的候选药物,但当前证据仅来自临床前模型和人肝细胞,尚需临床研究验证。

局限性

  • 研究为临床前动物模型及体外人类肝细胞实验,尚未在ACLD患者中进行临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: In advanced chronic liver disease (ACLD), deregulated hepatic necroinflammatory processes play a key role in the development of liver microvascular dysfunction, fibrogenesis, and increased hepatic vascular tone, resulting in progression of ACLD and portal hypertension. Given the current lack of an effective treatment, we aimed to characterise the effects of the pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist lanifibranor in 2 preclinical models of ACLD, as well as in liver cells from patients with ACLD. METHODS: Cirrhotic rats (thioacetamide or common bile duct ligation; TAA or cBDL) randomly received lanifibranor (100 mg/kg/day, po) or vehicle for 14 days (n = 12/group). PPAR expression, systemic and hepatic haemodynamics, presence of ascites, liver sinusoidal endothelial cell (LSEC) phenotype, hepatic stellate cell (HSC) activation, serum transaminases and albumin, hepatic macrophage infiltration, cytokine expression, and liver fibrosis were determined. Hepatic cells were isolated from the livers of patients with cirrhosis and their phenotype was evaluated after treatment with either lanifibranor or vehicle. RESULTS: TAA-cirrhotic rats receiving lanifibranor showed significantly lower portal pressure compared with vehicle-treated animals (-15%; p = 0.003) without decreasing portal blood flow, indicating improved hepatic vascular resistance. Moreover, lanifibranor-treated TAA-rats showed decreased ascites, improved LSEC and HSC phenotypes, ameliorated hepatic microvascular function, reduced hepatic inflammation, and significant fibrosis regression (-32%; p = 0.020). These findings were confirmed in the cBDL rat model as well as in human liver cells from patients with cirrhosis, which exhibited phenotypic improvement upon treatment with lanifibranor. CONCLUSIONS: Lanifibranor ameliorates fibrosis and portal hypertension in preclinical models of decompensated cirrhosis. Promising results in human hepatic cells further support its clinical evaluation for the treatment of ACLD. LAY SUMMARY: Advanced chronic liver disease (ACLD) constitutes a serious public health issue for which safe and effective treatments are lacking. This study shows that lanifibranor improves portal hypertension and liver fibrosis, 2 key elements of the pathophysiology of ACLD, in preclinical models of the disease. Evaluation of lanifibranor in liver cells from patients with ACLD further supports its beneficial effects.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Boyer-Diaz Z, Aristu-Zabalza P, Andrés-Rozas M, et al. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. J Hepatol. 2020. PMID: 33278455. doi:10.1016/j.jhep.2020.11.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。